Biological and Clinical Characterization of Novel lncRNAs Associated with Metastatic Prostate Cancer
Technical Report,15 Aug 2013,14 Aug 2015
Regents of the University of Michigan Ann Arbor United States
Pagination or Media Count:
Despite improvements in medical treatments over the past three decades, prostate cancer remains the second most common cause of cancer related deaths among U.S. men. According to National Cancer Institute, in 2012 241,000 prostate cancer diagnosis and 28,000 related deaths of American men were estimated. Androgen deprivation, surgery, andor radiotherapy in combination with chemotherapy has proven to be effective in treating patients that display localized disease however, progression to hormone refractory aggressive disease in a subset of prostate cancer patients remains the primary cause of mortality. The molecular mechanisms that contribute to the progression of localized disease into an aggressive disease remain largely unknown. Long non-coding RNAs lncRNAs have recently emerged as key players in tumor biology and can potentially serve as promising biomarkers. However, the vast majority of lncRNAs remain undiscovered or uncharacterized entities and their roles in prostate cancer are unclear.